AstraZeneca’s Breztri met primary endpoints in KALOS and LOGOS Phase III trials in asthma
Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease
Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease
Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA modelsfeatured in two peer-reviewed articles
Centre for Continuous Manufacturing and Advanced Crystallisation (CMAC) aims to accelerate the digital transformation of CMC development and manufacturing approaches
David joins HCTI with a distinguished career of over 22 years of corporate finance experience
The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date
Mantri will replace V. S. Mani, Executive Director & Global Chief Financial Officer of the company as he has conveyed his decision to opt for early retirement
In light of the contributions of these three institutes, it was decided to organize a CSIR Startup Conclave in Hyderabad. The event, scheduled for April 22–23, 2025
Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease
He has global experience in strategic and operational leadership levels with an extensive track record of leadership and success in building companies, businesses, teams, and brands for over 30 years
The acquisition of MDxK further strengthens the Business Unit’s position in the molecular diagnostics market
Subscribe To Our Newsletter & Stay Updated